Novo's Victoza Leads to Greater Weight Loss Than Byetta
Novo Nordisk A/S (NOVOB) said patients taking its Victoza diabetes drug had greater weight loss than those using Amylin Pharmaceuticals Inc. (AMLN)’s Byetta or a class of drug known as DPP-4 inhibitors.
Novo is presenting the data at the American Diabetes Association’s annual meeting in Philadelphia today. The company, which is studying Victoza as a possible obesity treatment, commented in an e-mailed statement.
Patients taking Victoza lost 3.9 kilograms (8.6 pounds) on average, compared with 0.8 kilogram for those on DPP-4 drugs and 2.9 kilograms for those taking Byetta, Novo Nordisk said.
To contact the reporter on this story: Phil Serafino in Paris at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com